Encellin is a biotechnology company based in San Francisco. Encellin is developing diabetes therapeutics using insulin responsive cells. Encellin aims to safely replace missing, damaged, or diseased cells in the body with next generation cell transplants.
In type 1 diabetes (T1D), if the cells that measure sugar and secrete insulin are missing, Encelling performs transplants. However, they are done in only the most severe cases.
Encellin is developing a novel thin-film cell encapsulation device for cell-based therapeutics. With an initial focus on diabetes Encellin plans to encapsulate and replace the cells responsible for making insulin, enabling patients to manage their disease, and have better control over their blood glucose levels.
Crystal Nyitray, PhD
Grace Wei, PhD
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.